Format

Send to

Choose Destination
J Pharm Sci. 2010 Jun;99(6):2557-75. doi: 10.1002/jps.22054.

Delivery of therapeutic proteins.

Author information

1
Department of Pharmaceutical Sciences, 521 Hochstetter Hall, University at Buffalo, The State University of New York, Amherst, New York 14260, USA.

Abstract

The safety and efficacy of protein therapeutics are limited by three interrelated pharmaceutical issues, in vitro and in vivo instability, immunogenicity and shorter half-lives. Novel drug modifications for overcoming these issues are under investigation and include covalent attachment of poly(ethylene glycol) (PEG), polysialic acid, or glycolic acid, as well as developing new formulations containing nanoparticulate or colloidal systems (e.g., liposomes, polymeric microspheres, polymeric nanoparticles). Such strategies have the potential to develop as next generation protein therapeutics. This review includes a general discussion on these delivery approaches.

PMID:
20049941
PMCID:
PMC2857543
DOI:
10.1002/jps.22054
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center